Overview

A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
A single-arm trial using Tocilizumab for acute GVHD prophylaxis after haploidentical HSCT.
Phase:
Phase 2
Details
Lead Sponsor:
Yi Luo
Treatments:
Antilymphocyte Serum
Busulfan
Cyclophosphamide
Cyclosporine
Cyclosporins
Cytarabine
Mycophenolic Acid
Thymoglobulin